Drug Profile
Research programme: cancer therapeutics - Aria Pharmaceuticals
Latest Information Update: 11 May 2021
Price :
$50
*
At a glance
- Originator twoXAR
- Developer Aria Pharmaceuticals; Stanford University School of Medicine
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 04 May 2021 twoXAR Pharmaceuticals is now called Aria Pharmaceuticals
- 28 Apr 2021 No recent reports of development identified for preclinical development in Liver-cancer in USA
- 13 Mar 2017 Preclinical trials in liver cancer in USA before March 2017 (unspecified route)